259 related articles for article (PubMed ID: 22709412)
1. Atypical fibroxanthoma.
Ziemer M
J Dtsch Dermatol Ges; 2012 Aug; 10(8):537-50. PubMed ID: 22709412
[TBL] [Abstract][Full Text] [Related]
2. Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy.
Koch M; Freundl AJ; Agaimy A; Kiesewetter F; Künzel J; Cicha I; Alexiou C
Anticancer Res; 2015 Nov; 35(11):5717-35. PubMed ID: 26503993
[TBL] [Abstract][Full Text] [Related]
3. Atypical fibroxanthoma and malignant fibrous histiocytoma of the skin.
Rizzardi C; Angiero F; Melato M
Anticancer Res; 2003; 23(2C):1847-51. PubMed ID: 12820468
[TBL] [Abstract][Full Text] [Related]
4. Atypical fibroxanthoma: new insights.
Hussein MR
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1075-88. PubMed ID: 24958232
[TBL] [Abstract][Full Text] [Related]
5. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Nikaido O; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Jun; 14(6):581-8. PubMed ID: 11406660
[TBL] [Abstract][Full Text] [Related]
6. Atypical fibroxanthoma and malignant fibrous histiocytoma.
Withers AH; Brougham ND; Barber RM; Tan ST
J Plast Reconstr Aesthet Surg; 2011 Nov; 64(11):e273-8. PubMed ID: 21664889
[TBL] [Abstract][Full Text] [Related]
7. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma.
Hollmig ST; Rieger KE; Henderson MT; West RB; Sundram UN
Am J Dermatopathol; 2013 Apr; 35(2):176-9. PubMed ID: 23000905
[TBL] [Abstract][Full Text] [Related]
8. Superficial malignant fibrous histiocytoma presenting as recurrent atypical fibroxanthoma.
Ly H; Selva D; James CL; Huilgol SC
Australas J Dermatol; 2004 May; 45(2):106-9. PubMed ID: 15068457
[TBL] [Abstract][Full Text] [Related]
9. [Atypical fibroxanthoma and pleomorphic dermal sarcoma].
Ziemer M; Jäger IM; Dippel E
Hautarzt; 2019 Sep; 70(9):661-669. PubMed ID: 31468069
[TBL] [Abstract][Full Text] [Related]
10. Correction and clarification regarding AFX and pleomorphic dermal sarcoma.
McCalmont TH
J Cutan Pathol; 2012 Jan; 39(1):8. PubMed ID: 22211329
[No Abstract] [Full Text] [Related]
11. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience.
McCoppin HH; Christiansen D; Stasko T; Washington C; Martinez JC; Brown MD; Zwald FO
Dermatol Surg; 2012 Feb; 38(2):230-9. PubMed ID: 22129349
[TBL] [Abstract][Full Text] [Related]
12. AFX: what we now know.
McCalmont TH
J Cutan Pathol; 2011 Nov; 38(11):853-6. PubMed ID: 21955311
[No Abstract] [Full Text] [Related]
13. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.
Clarke LE; Frauenhoffer E; Fox E; Neves R; Bruggeman RD; Helm KF
J Cutan Pathol; 2010 Jul; 37(7):737-43. PubMed ID: 20175824
[TBL] [Abstract][Full Text] [Related]
14. Atypical fibroxanthoma.
Weedon D; Van Deurse M
J Cutan Pathol; 2012 May; 39(5):565. PubMed ID: 22443422
[No Abstract] [Full Text] [Related]
15. H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2001 Nov; 32(11):1225-31. PubMed ID: 11727262
[TBL] [Abstract][Full Text] [Related]
16. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
Soleymani T; Tyler Hollmig S
Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
[TBL] [Abstract][Full Text] [Related]
17. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma.
Gleason BC; Calder KB; Cibull TL; Thomas AB; Billings SD; Morgan MB; Hiatt KM; Smoller BR
J Cutan Pathol; 2009 May; 36(5):543-7. PubMed ID: 19476522
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
19. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.
Hartel PH; Jackson J; Ducatman BS; Zhang P
J Cutan Pathol; 2006 Sep; 33 Suppl 2():24-8. PubMed ID: 16972949
[TBL] [Abstract][Full Text] [Related]
20. h-caldesmon immunoreactivity in atypical fibroxanthoma: implications for the differential diagnosis.
Martinez-Ciarpaglini C; Agustí J; Alvarez E; Hueso L; Terrádez L; Monteagudo C
Pathology; 2018 Apr; 50(3):358-361. PubMed ID: 29490873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
